Sale!

Comprehensive Tumor Panel 270 Genes and PD-L1 Test

9,000 د.إ

-25%

The Comprehensive Tumor Panel 270 Genes and PD-L1 Test is a cutting-edge diagnostic tool available at DNA Labs UAE, designed to provide a detailed genetic profile of tumors. Priced at 9000 AED, this test analyzes 270 genes associated with various cancers, offering insights into the genetic alterations and mutations that could be driving the growth and spread of cancer cells. Additionally, it includes an assessment for PD-L1, a protein that plays a critical role in the body’s immune response to cancer. By evaluating the presence and expression level of PD-L1, this test can help in identifying patients who are likely to benefit from immunotherapy treatments. This comprehensive approach not only aids in the accurate diagnosis and understanding of an individual’s cancer but also guides personalized treatment strategies, enhancing the potential for successful outcomes.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

Comprehensive Tumor Panel 270 Genes and PDL1 Test

Test Name: Comprehensive Tumor Panel 270 Genes and PDL1 Test

Components: DNA analysis of 270 genes and evaluation of PDL1 protein expression

Price: 9000.0 AED

Sample Condition: Biopsy

Report Delivery Method: Test results will be delivered through the preferred method

Test Type: Genetic test

Doctor: Your trusted healthcare professional

Test Department: DNA Labs UAE

Pre Test Information

The Comprehensive Tumor Panel 270 Genes and PDL1 Test is a genetic test designed to analyze the DNA of a tumor. By identifying mutations and other genetic changes, this test can provide valuable insights into the growth and spread of cancer.

Test Details

The panel examines 270 genes commonly associated with various types of cancer, such as lung, breast, colon, and melanoma. Additionally, it evaluates the expression of the PDL1 protein, which plays a role in regulating the immune system’s response to cancer cells.

By identifying specific genetic alterations in a tumor, the Comprehensive Tumor Panel allows doctors to develop personalized treatment plans tailored to each patient’s unique cancer characteristics. For example, if a patient’s tumor has a mutation in a gene known to be sensitive to a particular drug, the doctor may recommend that drug as part of the treatment regimen. Similarly, if the tumor shows high levels of PDL1 expression, immunotherapy drugs targeting this protein may be considered.

The Comprehensive Tumor Panel 270 Genes and PDL1 Test is a valuable tool that helps guide cancer treatment decisions, ultimately improving outcomes for patients.

Test Name Comprehensive Tumor Panel 270 Genesand PDL1 Test
Components
Price 9000.0 AED
Sample Condition Biopsy
Report Delivery
Method
Test type
Doctor
Test Department:
Pre Test Information
Test Details

The Comprehensive Tumor Panel 270 Genes+ PDL1 is a genetic test that analyzes the DNA of a tumor to identify mutations and other genetic changes that may be driving the growth and spread of cancer. The panel examines 270 genes that are commonly mutated in various types of cancer, including lung, breast, colon, and melanoma, among others. In addition, the test also evaluates the expression of the PDL1 protein, which is involved in regulating the immune system’s response to cancer cells.

By identifying specific genetic alterations in a tumor, the Comprehensive Tumor Panel can help doctors develop personalized treatment plans that target the unique characteristics of each patient’s cancer. For example, if a patient’s tumor has a mutation in a gene that is known to be sensitive to a particular drug, the doctor may recommend that drug as part of the patient’s treatment regimen. Similarly, if the tumor has high levels of PDL1 expression, the doctor may consider immunotherapy drugs that target this protein.

Overall, the Comprehensive Tumor Panel 270 Genes+ PDL1 is a valuable tool for guiding cancer treatment decisions and improving outcomes for patients.